Between January and April 2018, Russia imported 156.1 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms 0.9% higher than that of the same period of 2017, and 35.9 bln RUB worth of in-bulk drugs, which is 27% higher than those of the same period of 2017. In total, the dynamics in monetary terms are 0.5%.

In April 2018, Russia imported 42.1 bln RUB worth of ready-made drugs (free circulation prices), which is in monetary terms 2.8% higher than that of April 2017, and 11.5 bln RUB worth of in-bulk drugs, which is 1,5 times higher than that of April 2017.

In physical terms, Russia imported 572.2 mln units of ready-made [pharmaceuticals between January and April 2018, which is 7.9% lower than that of the same period of 2017. The April dynamics are even worse, with -15%, the lowest over the past 18 months. In total, Russia imported 131.6 mln units of pharmaceuticals in April 2018. When calculated in minimum dosage units (MDU), the dynamics are -21% for April and -5.5% for the period between January and April.

The dynamics of the in-bulk import are 6.3% for the first 4 months, when calculated in MDU, but the total dynamics for the period are -4.2%.

Recordati Group, Danapha Pharmaceutical, and Adgio have the lowest dynamics in physical terms over the period between January and April 2018, with -69%, -61%, and -49%, respectively. Not only has the French Recordati Group stopped importing 7 products, it has also decreased the import of 7 of the 10 remaining products that are still imported, in particular Hexaspray, Otofa, and Isofra. Danapha Pharmaceutical, famous for its Golden Star Balm, has decreased its import by 58%. The import of Adgio is decreasing due to smaller import lines. While the dynamics for its other products are stable, the dynamics for Prednisone are worrisome.

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – April 2018)